Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

BMY Bristol Myers Squibb Co

57,958

2,13 (3,81%)

Após o horário de negociação

Última atualização: 20:22:25

Atrasado em 15 minutos

Investors Watching Two Small-Caps for News on Potential Major Advancements in Cancer Treatments

Both Shuttle Pharmaceuticals (Nasdaq:SHPH) and Northwest Biotherapeutics

To read the full story on AllPennyStocks.com, click here.

Bristol Myers Squibb (NYSE:BMY)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025

Click aqui para mais gráficos Bristol Myers Squibb.

Bristol Myers Squibb (NYSE:BMY)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025

Click aqui para mais gráficos Bristol Myers Squibb.

Notícias Bristol Myers Squibb Co

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy® for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...
Segunda, 24 de Fevereiro de 2025 (12 horas atrás) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Sexta, 21 de Fevereiro de 2025 (3 dias atrás) • Edgar (US Regulatory)

Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer
Quarta, 19 de Fevereiro de 2025 (6 dias atrás) • Business Wire

New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis
Domingo, 16 de Fevereiro de 2025 (1 semana atrás) • Business Wire

Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
Quinta, 13 de Fevereiro de 2025 (2 semanas atrás) • Business Wire

Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma
Segunda, 10 de Fevereiro de 2025 (2 semanas atrás) • Business Wire

Form 8-K - Current report
Quinta, 6 de Fevereiro de 2025 (3 semanas atrás) • Edgar (US Regulatory)

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
Quinta, 6 de Fevereiro de 2025 (3 semanas atrás) • Business Wire

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
Sexta, 31 de Janeiro de 2025 (4 semanas atrás) • Business Wire

Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
Sexta, 31 de Janeiro de 2025 (4 semanas atrás) • Business Wire

Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy...
Sábado, 25 de Janeiro de 2025 (1 mês atrás) • Business Wire

Investors Watching Two Small-Caps for News on Potential Major Advancements in Cancer Treatments
Segunda, 13 de Janeiro de 2025 (1 mês atrás) • AllPennyStocks.com

Mais Notícias de Bristol Myers Squibb Co

US Dollar vs BRL

US Dollar vs Sterling

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições